Host-Pathogen Interaction: Antimicrobial Pharmacology

Clinical meaning

Antimicrobial pharmacology requires the NP to integrate understanding of pathogen biology, drug mechanisms, pharmacokinetic/pharmacodynamic (PK/PD) principles, and stewardship concepts to optimize treatment outcomes while minimizing resistance development.

Antimicrobial mechanisms are classified by their molecular targets. Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) inhibit bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs) and preventing transpeptidation of peptidoglycan cross-links, leading to osmotic lysis. They exhibit time-dependent killing, meaning efficacy correlates with the duration that free drug concentration exceeds the MIC (fT>MIC). Aminoglycosides (gentamicin, tobramycin, amikacin) bind the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins; they exhibit concentration-dependent killing with a post-antibiotic effect, making once-daily extended-interval dosing effective. Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) inhibit DNA gyrase and topoisomerase IV, preventing DNA supercoiling and replication; they also demonstrate concentration-dependent killing. Macrolides (azithromycin, erythromycin, clarithromycin) bind the 50S ribosomal subunit blocking peptide translocation; primarily bacteriostatic. Vancomycin binds D-Ala-D-Ala terminal of peptidoglycan precursors, preventing cell wall cross-linking; effective against gram-positive organisms only because the large molecule cannot penetrate gram-negative outer membranes.

PK/PD optimization is essential for treatment success. Time-dependent antibiotics (beta-lactams, carbapenems) are optimized with extended or continuous infusions to maximize fT>MIC. Concentration-dependent antibiotics (aminoglycosides, fluoroquinolones, daptomycin) are optimized with high peak concentrations relative to MIC (Cmax/MIC ratio or AUC/MIC ratio). Vancomycin efficacy is guided by AUC/MIC targeting (goal AUC/MIC 400-600 for MRSA), replacing traditional trough-based monitoring per updated 2020 consensus guidelines.

Diagnosis & workup

Diagnostics & workup: - Blood cultures (minimum 2 sets from separate venipuncture sites BEFORE antibiotics): identify causative organism and guide de-escalation; false-positive rate 2-3% per set - Gram stain: rapid preliminary identification — gram-positive cocci in clusters (Staphylococcus), gram-positive cocci in chains (Streptococcus), gram-negative rods (Enterobacteriaceae, Pseudomonas) - Culture and sensitivity (C&S) with minimum inhibitory concentration (MIC): identifies specific organism and quantifies susceptibility to each antibiotic; guides targeted narrow-spectrum therapy - Procalcitonin (PCT): differentiates bacterial from viral infection; guides antibiotic initiation (>0.5 ng/mL suggests bacterial) and duration (serial levels guide safe discontinuation) - Therapeutic drug monitoring (TDM): vancomycin AUC-guided dosing (target AUC/MIC 400-600 for MRSA), aminoglycoside peak and trough levels, monitor for nephrotoxicity and ototoxicity - Antibiogram: institution-specific cumulative antibiotic susceptibility report updated annually; guides empiric antibiotic selection based on local resistance patterns - Rapid molecular diagnostics: PCR-based panels (blood culture identification panels, respiratory panels) providing organism identification and resistance gene detection within hours rather than days - C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR): nonspecific inflammatory markers useful for monitoring treatment response and identifying treatment failure

Risk factors: - Prior antibiotic exposure within 90 days (selects for resistant organisms and disrupts normal flora) - Healthcare-associated acquisition: hospitalization >48 hours, nursing home residence, hemodialysis, wound care clinic attendance - Invasive devices: central venous catheters, urinary catheters, mechanical ventilation creating biofilm-associated infections - Immunosuppression: neutropenia (ANC <500), organ transplant, HIV with CD4 <200, chronic corticosteroid therapy - Structural lung disease (bronchiectasis, cystic fibrosis) harboring resistant organisms such as Pseudomonas - International travel to regions with high antimicrobial resistance (Southeast Asia, South Asia — ESBL and carbapenem-resistant organisms) - Age extremes: neonates (immature immune function, limited drug metabolism) and elderly (immunosenescence, polypharmacy, renal impairment affecting drug clearance) - Chronic kidney disease requiring dose adjustment of renally-eliminated antibiotics; failure to adjust increases toxicity risk

Clinical meaning

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Clinical meaning

Practice questions for this topic

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT

Diagnosis & workup

Practice questions for this topic

Your next step on PMHNP

Practice this topic

Review related lessons

PMHNP CAT